Literature DB >> 26103152

Risk of cancer of unknown primary after hospitalization for autoimmune diseases.

Kari Hemminki1,2, Kristina Sundquist1,3, Jan Sundquist1,3, Jianguang Ji1.   

Abstract

Cancer of unknown primary (CUP) is a heterogeneous syndrome diagnosed at metastatic sites. The etiology is unknown but immune dysfunction may be a contributing factor. Patients with autoimmune diseases were identified from the Swedish Hospital Discharge Register and linked to the Swedish Cancer Registry. Standardized incidence ratios (SIRs) were calculated for subsequent CUP and compared with subjects without autoimmune diseases. A total of 789,681 patients were hospitalized for any of 32 autoimmune diseases during years 1964-2012; 2,658 developed subsequent CUP, giving an overall SIR of 1.27. A total of 16 autoimmune diseases were associated with an increased risk for CUP; polymyositis/dermatomyositis showed the highest SIR of 3.51, followed by primary biliary cirrhosis (1.81) and Addison's disease (1.77). CUP risk is known to be reduced in long-time users of pain-relieving nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin. For patients with ankylosing spondylitis and with some other autoimmune diseases, with assumed chronic medication by NSAIDSs, CUP risks decreased in long-term follow-up. The overall risk of CUP was increased among patients diagnosed with autoimmune diseases, which call for clinical attention and suggest a possible role of immune dysfunction in CUP. The associations with many autoimmune diseases were weak which may imply that autoimmunity may not synergize with CUP-related immune dysfunction. However, long-term NSAID medication probably helped to curtail risks in some autoimmune diseases and CUP risks were generally higher in autoimmune diseases for which NSAIDs are not used and for these CUP appears to be a serious side effect.
© 2015 UICC.

Entities:  

Keywords:  autoimmune diseases; cancer of unknown primary; national databases

Mesh:

Year:  2015        PMID: 26103152     DOI: 10.1002/ijc.29657

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

Review 1.  Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Chuiwen Deng; Wenli Li; Yunyun Fei; Yongzhe Li; Fengchun Zhang
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

2.  Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.

Authors:  Ahuva Averin; Amanda Silvia; Lois Lamerato; Kathryn Richert-Boe; Manpreet Kaur; Devi Sundaresan; Neel Shah; Mark Hatfield; Tatiana Lawrence; Gary H Lyman; Derek Weycker
Journal:  Support Care Cancer       Date:  2020-09-03       Impact factor: 3.603

3.  Association of Family History of Type 2 Diabetes with Prostate Cancer: A National Cohort Study.

Authors:  Jianguang Ji; Jan Sundquist; Kristina Sundquist
Journal:  Front Oncol       Date:  2016-08-29       Impact factor: 6.244

4.  Family history of cancer in first degree relatives and risk of cancer of unknown primary.

Authors:  Alexander L R Grewcock; Karlijn E P E Hermans; Matty P Weijenberg; Piet A van den Brandt; Caroline Loef; Rob L H Jansen; Leo J Schouten
Journal:  Eur J Cancer Care (Engl)       Date:  2021-07-05       Impact factor: 2.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.